The role of SRC family kinases in prostate cancer.
作者信息
Tatarov Oleg, Edwards Joanne
机构信息
Section of Surgery, Division of Cancer Sciences and Molecular Pathology, University of Glasgow, Royal Infirmary, Glasgow, G31 2ER.
出版信息
Transl Oncogenomics. 2007 Oct 14;2:67-77. Print 2007.
Abstract
摘要
相似文献
1
The role of SRC family kinases in prostate cancer.
Transl Oncogenomics. 2007 Oct 14;2:67-77. Print 2007.
2
The role of Src in prostate cancer.
Ann Oncol. 2007 Nov;18(11):1765-73. doi: 10.1093/annonc/mdm086. Epub 2007 Apr 10.
3
Targeting tyrosine kinases and autophagy in prostate cancer.
Horm Cancer. 2011 Feb;2(1):38-46. doi: 10.1007/s12672-010-0053-3. Epub 2010 Dec 2.
4
Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.
Oncogene. 2008 Oct 23;27(49):6365-75. doi: 10.1038/onc.2008.250. Epub 2008 Aug 4.
5
SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy.
Anticancer Agents Med Chem. 2007 Nov;7(6):651-9. doi: 10.2174/187152007784111278.
6
Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase.
Mol Cell Biol. 2001 Dec;21(24):8385-97. doi: 10.1128/MCB.21.24.8385-8397.2001.
7
Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK.
Oncogene. 2004 Mar 18;23(12):2197-205. doi: 10.1038/sj.onc.1207344.
8
CTA095, a novel Etk and Src dual inhibitor, induces apoptosis in prostate cancer cells and overcomes resistance to Src inhibitors.
PLoS One. 2013 Aug 15;8(8):e70910. doi: 10.1371/journal.pone.0070910. eCollection 2013.
9
c-Src is required for hypoxia-induced metastasis-associated functions in prostate cancer cells.
Onco Targets Ther. 2019 May 8;12:3519-3529. doi: 10.2147/OTT.S201320. eCollection 2019.
10
Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.
Expert Opin Investig Drugs. 2010 May;19(5):605-14. doi: 10.1517/13543781003789388.
引用本文的文献
1
Androgen receptor regulates SRC expression through microRNA-203.
Oncotarget. 2016 May 3;7(18):25726-41. doi: 10.18632/oncotarget.8366.
2
Loss of Androgen-Regulated MicroRNA 1 Activates SRC and Promotes Prostate Cancer Bone Metastasis.
Mol Cell Biol. 2015 Jun 1;35(11):1940-51. doi: 10.1128/MCB.00008-15. Epub 2015 Mar 23.
3
SRC: marker or actor in prostate cancer aggressiveness.
Front Oncol. 2014 Aug 18;4:222. doi: 10.3389/fonc.2014.00222. eCollection 2014.
4
Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models.
PLoS One. 2010 Oct 19;5(10):e13500. doi: 10.1371/journal.pone.0013500.
本文引用的文献
1
A SARCOMA OF THE FOWL TRANSMISSIBLE BY AN AGENT SEPARABLE FROM THE TUMOR CELLS.
J Exp Med. 1911 Apr 1;13(4):397-411. doi: 10.1084/jem.13.4.397.
2
Inhibition of the SH3 domain-mediated binding of Src to the androgen receptor and its effect on tumor growth.
Oncogene. 2007 Oct 11;26(46):6619-29. doi: 10.1038/sj.onc.1210487. Epub 2007 May 7.
3
Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.
Cancer Res. 2007 Mar 15;67(6):2800-8. doi: 10.1158/0008-5472.CAN-06-3469.
4
Nonreceptor tyrosine kinases in prostate cancer.
Neoplasia. 2007 Feb;9(2):90-100. doi: 10.1593/neo.06694.
5
Interaction of Pyk2 and PTP-PEST with leupaxin in prostate cancer cells.
Am J Physiol Cell Physiol. 2007 Jun;292(6):C2288-96. doi: 10.1152/ajpcell.00503.2006. Epub 2007 Feb 28.
6
Cancer statistics, 2007.
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66. doi: 10.3322/canjclin.57.1.43.
7
Inappropriate activation of the androgen receptor by nonsteroids: involvement of the Src kinase pathway and its therapeutic implications.
Cancer Res. 2006 Nov 1;66(21):10449-59. doi: 10.1158/0008-5472.CAN-06-2582.
8
N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor.
J Med Chem. 2006 Nov 2;49(22):6465-88. doi: 10.1021/jm060434q.
9
SRC inhibitors in metastatic bone disease.
Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6291s-6295s. doi: 10.1158/1078-0432.CCR-06-0991.
10
Regulation of androgen receptor activity by tyrosine phosphorylation.
Cancer Cell. 2006 Oct;10(4):309-19. doi: 10.1016/j.ccr.2006.08.021.
Zotero 插件